China to India: Herbal Import Trade Route

The China to India Herbal corridor is one of India's established pharmaceutical import routes from China, with 1 shipments documented worth a combined $405.8K USD. The route is dominated by NOVOZYMES A/S , which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of China's herbal export sector.

Across 1 active China suppliers, the average shipment value stands at $405.8K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 71% of all shipments, consistent with herbal's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 25 days port-to-port. The route has recorded an annual growth rate of 11.7%, placing it at rank #1 among India's top herbal import origins globally.

On the Indian buyer side, key Indian importers include NOVOZYMES SOUTH ASIA PRIVATE LIMITED . NOVOZYMES SOUTH ASIA PRIVATE LIMITED is the single largest Indian importer with 1 shipments valued at $405.8K USD.

India's herbal imports from China are driven primarily by a handful of large-scale China manufacturers. NOVOZYMES A/S with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from China supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — NOVOZYMES A/S — together account for 100% of total trade value on this route. The average shipment value of $405.8K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

On the buying side, NOVOZYMES SOUTH ASIA PRIVATE LIMITED is the largest importer with 1 shipments worth $405.8K USD — representing 100% of all herbal imports from China on this route.